^
    Back
    Association details:
    Biomarker:ALK mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:deulorlatinib (TGRX-326) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.

    Published date:
    05/25/2023
    Excerpt:
    Eleven ALK mutations were detected in 16 pts (either alone or in combination); 50.0% pts achieved PR….TGRX-326 demonstrated antitumor activity against multiple ALK mutations including G1202R.
    DOI:
    10.1200/JCO.2023.41.16_suppl.9113
    Trial ID:
    NCT05441956